Our Company
Xanamem^® (emestedastat)
Clinical Trials
Investor Centre
News
Contact Us

BACK TO NEWS

James Campbell • 14 Oct 2022

2022 Annual Report to Shareholders

Enjoyed this read?

Stay up to date with our latest research.

Related articles

Press Releases and Media

Dementia disaster warning

Daily Telegraph • April 2, 2025

Press Releases and Media

Top of mind: ASX companies tackling neurological disorders

The Australian • March 26, 2025

Press Releases and Media

Executive Interview HotCopper with Dr Steven Gourlay: Xanamem: Alzheimer’s breakthrough set for 2025, 2026

HotCopper • March 5, 2025

Our Company
Xanamem^® (emestedastat)

Clinical Trials

Investors
News
Contact Us
Target Market Determination

Copyright © 2025 Actinogen